Stock listing

NYSE American:APUS Apimeds Pharmaceuticals US, Inc. Stock

Home listing (NYSE American) of Apimeds Pharmaceuticals US, Inc.

Follow Apimeds Pharmaceuticals US, Inc. into a list and get an email when it puts out news.

Share price · AMEX:APUS

$1.60 USD -0.29 (-15.3%)

Close on Nov 20, 2026

Past year -93.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.51 – $1.77 USDNov 20, 2026
Volume
48,552 sharesNov 20, 2026
Market cap
$2.41M USDAt the close on Nov 20, 2026 · price × 1.51M shares outstanding
52-week range
$1.51 – $59.70 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$21.32M USDMedian day 64,744 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Apimeds Pharmaceuticals US, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:APUS · Home$1.60 USD-0.29 (-15.3%)48,552$1.77$1.77$1.51$1.89Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:APUS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.60-0.29-15.3%$1.77$1.77$1.5148,552
$1.89-0.06-3.1%$2.12$2.28$1.78388,893
$1.95-0.09-4.4%$2.04$2.04$1.8442,027
$2.04-0.19-8.5%$2.22$2.22$2.0318,018
$2.23-0.04-1.8%$2.50$2.50$2.1830,940
$2.27-0.09-3.8%$2.29$2.37$2.2028,691
$2.36-0.33-12.3%$2.62$2.68$2.2263,434
$2.69-0.01-0.4%$2.68$2.735$2.6011,588
$2.70-0.005-0.2%$2.68$2.735$2.61130,311
$2.705-0.025-0.9%$2.67$2.738$2.5415,082
$2.73-0.19-6.5%$3.00$3.00$2.6064,744
$2.92-0.05-1.7%$2.98$2.98$2.6811,207
$2.97+0.08+2.8%$2.825$2.97$2.7324,410
$2.89-0.12-4.0%$3.01$3.02$2.7838,230
$3.01-0.20-6.2%$3.11$3.11$2.8420,052
$3.21+0.14+4.6%$2.89$3.21$2.8348,752
$3.07+0.02+0.7%$2.39$3.095$2.3968,288
$3.05+0.155+5.4%$2.90$3.05$2.65143,086
$2.895+0.005+0.2%$2.92$3.06$2.71329,730
$2.89-0.27-8.5%$3.07$3.175$2.8135,400
$3.16-0.09-2.8%$3.14$3.25$3.0642,300
$3.25-0.16-4.7%$3.51$3.57$3.005128,000
$3.41-0.09-2.6%$3.43$3.55$3.2166,000
$3.50-0.54-13.4%$3.92$3.95$3.40101,700
$4.04-0.35-8.0%$4.16$4.35$3.9043,200
$4.39-0.19-4.1%$4.25$4.415$4.00109,000
$4.58-0.04-0.9%$4.60$4.81$4.25235,300
$4.62-0.58-11.2%$4.87$4.91$4.26339,800
$5.20+0.18+3.6%$5.43$6.036$4.9711,394,300
$5.02-0.49-8.9%$5.54$5.72$4.403,346,300
$5.51-1.54-21.8%$6.43$6.496$5.211,112,800
$7.05-0.08-1.1%$8.00$9.84$6.8622,395,400
$7.13+2.54+55.3%$4.91$8.39$4.7143,838,600
$4.59+1.37+42.5%$4.99$5.83$4.2133,787,400
$3.22-0.88-21.5%$4.10$4.16$3.10138,400
$4.10-0.90-18.0%$4.90$5.09$4.10145,800
$5.00-0.02-0.4%$5.04$5.25$4.72190,100
$5.02-1.37-21.4%$6.17$6.17$4.63762,100
$6.39-0.86-11.9%$6.33$6.50$5.56858,800
$7.25+2.33+47.4%$8.32$9.14$5.3937,114,300
$4.92+2.63+114.8%$6.99$8.74$4.6187,850,200
$2.29+0.44+23.8%$1.81$2.30$1.745152,500
$1.85+0.18+10.8%$1.65$1.999$1.613132,400
$1.67-0.10-5.6%$1.72$1.865$1.67671,000
$1.77+0.10+6.0%$1.68$2.10$1.631,335,500
$1.67+0.07+4.4%$1.73$1.92$1.6083,900
$1.60-0.04-2.4%$1.71$1.71$1.5164,300
$1.64-0.45-21.5%$2.11$2.11$1.6066,200
$2.09-0.015-0.7%$2.39$2.39$2.02529,800
$2.105-0.065-3.0%$2.16$2.26$2.0920,700
$2.17-0.12-5.2%$2.26$2.47$2.1240,600
$2.29-0.01-0.4%$2.30$2.35$2.1729,500
$2.30-0.12-5.0%$2.40$2.405$2.2517,421
$2.42-0.09-3.6%$2.49$2.60$2.4224,400
$2.51-0.12-4.6%$2.66$2.71$2.4050,600
$2.63-0.91-25.7%$3.17$3.38$2.5184,100
$3.54-0.34-8.8%$3.87$3.87$3.4129,200
$3.88+0.01+0.3%$4.09$4.09$3.738,200
$3.87-0.08-2.0%$4.10$4.10$3.8619,100
$3.95-0.65-14.1%$4.63$4.81$3.737172,200
$4.60-0.37-7.4%$4.74$4.99$4.358230,135
$4.97+0.22+4.6%$4.78$5.35$4.6549,100
$4.75-0.09-1.9%$4.34$4.75$4.3415,900
$4.84+0.45+10.3%$4.30$5.43$4.175559,500
$4.390.000.0%$4.23$4.50$4.09117,200

Splits

1 split · AMEX:APUS · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
NYSE American:APUS
Asset type
Stock
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All Apimeds Pharmaceuticals US, Inc. news

Apimeds Pharmaceuticals US, Inc. on 6ix

News releases
14 in the last 12 months · 23 in all · newest Nov 18, 2026 · oldest 2025
Decks
2 decks · latest July 2025

Where Apimeds Pharmaceuticals US, Inc. is listed

ListingExchangeCountryCurrency
NYSE American:APUS · Home listing · This pageNYSE AmericanUnited StatesUSD
BOATS:APUSBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$12.01M USD
P/E
Loss
EV/sales
3.8×
EV/EBITDA
Negative EBITDA
Price/book
0.0×
Gross margin
Not reported
Operating margin
−737.8%
Net margin
−714.8%
Debt to equity
0.1×
Beta vs S&P 500
1.25

Team and board

Officers

OfficerRole
Sungjoon ChaeCo-Chief Executive Officer
Vin MenonChief Executive Officer and Director
Eric SherbChief Financial Officer
Brian PetersSenior Vice President, ai² Division
Susan KramerSenior Vice President, Development
Christopher KimChief Scientific Officer

Board

DirectorRole
Bennett WeintraubDirector
Carol O’DonnellDirector
Elona KoganDirector
Jakap KooDirector
Sungjoon ChaeCo-Chief Executive Officer
Vin MenonChief Executive Officer and Director

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026−12.6%
Q2 2026Aug 14, 2026−8.9%
Q3 2025Nov 12, 2025+4.5%
Q2 2025Aug 19, 2025+3.4%
Q1 2025May 19, 2025+8.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2025)Investor deck24 slidesJuly 2025
IPO Roadshow (February 2025)IPO roadshow30 slidesFeb 10, 2025

Open Decks

Financings

RaiseDate
Private placement of pIPE financing
Closed: US$100M raised · E.F. Hutton & Co.
Dealers: E.F. Hutton & Co. (lead)
Use of proceeds: Ten percent of net proceeds to new subsidiary Newco, ninety percent to MindWave
May 5, 2026
Public offering of shares of common stock
Closed: US$13.5M raised · US$4 a share · D. Boral Capital LLC
Dealers: D. Boral Capital LLC (lead)
Use of proceeds: Phase III knee osteoarthritis trial, a multiple sclerosis sponsorship study, product manufacturing and general working capital
May 12, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$4.00 a share on May 8, 2025.

Price
US$4.00 a share
Shares offered
3,375,000 shares of common stock
Offering size
US$13.5 million
Underwriters' option
Up to 506,250 more shares
Listing
APUS on NYSE American
Shares delivered
On or about May 12, 2025

Steps

StepWhen
Draft sent to the SEC in confidenceJan 29, 2024
Filed publiclySep 25, 2024
Amended 10 timesNewest May 2, 2025
Shares registered with an exchangeMar 3, 2025
Declared effective by the SECMay 5, 2025
Final prospectus, with the priceMay 9, 2025

Filings

FilingFiled
424B4 · ProspectusMay 9, 2025
EFFECT · Notice that a registration is effectiveMay 5, 2025
CORRESP · Letter to the SECMay 5, 2025
CORRESP · Letter to the SECMay 5, 2025
UPLOAD · Letter from the SECMay 5, 2025
POS AM · Amendment to an effective registrationMay 2, 2025
CORRESP · Letter to the SECMay 1, 2025
CORRESP · Letter to the SECMay 1, 2025
POS AM · Amendment to an effective registrationMay 1, 2025
UPLOAD · Letter from the SECMay 1, 2025
All 39 filings
FilingFiled
UPLOAD · Letter from the SECApr 30, 2025
POS AM · Amendment to an effective registrationApr 17, 2025
CERT · Exchange's certificate of listingMar 4, 2025
8-A12B · Registration of shares for listing on an exchangeMar 3, 2025
EFFECT · Notice that a registration is effectiveFeb 11, 2025
FWP · Free writing prospectusFeb 10, 2025
CORRESP · Letter to the SECFeb 10, 2025
S-1/A · Registration statement, amendedFeb 10, 2025
UPLOAD · Letter from the SECFeb 7, 2025
CORRESP · Letter to the SECFeb 7, 2025
CORRESP · Letter to the SECFeb 7, 2025
S-1/A · Registration statement, amendedFeb 6, 2025
S-1/A · Registration statement, amendedJan 29, 2025
S-1/A · Registration statement, amendedJan 10, 2025
S-1/A · Registration statement, amendedDec 20, 2024
CORRESP · Letter to the SECDec 19, 2024
UPLOAD · Letter from the SECDec 16, 2024
S-1/A · Registration statement, amendedDec 9, 2024
S-1/A · Registration statement, amendedNov 8, 2024
S-1 · Registration statementSep 25, 2024
DRS/A · Draft registration statement, amendedAug 5, 2024
DRSLTR · Letter to the SEC with a draftAug 2, 2024
DRS/A · Draft registration statement, amendedJun 17, 2024
DRSLTR · Letter to the SEC with a draftJun 14, 2024
UPLOAD · Letter from the SECMay 23, 2024
DRSLTR · Letter to the SEC with a draftMay 13, 2024
DRS/A · Draft registration statement, amendedMay 13, 2024
UPLOAD · Letter from the SECFeb 26, 2024
DRS · Draft registration statementJan 29, 2024

Open IPO · From the cover of the final prospectus (424B4) filed May 9, 2025

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue00000
Cost of revenue5.71K
Gross profit-5.71K
Research and development1.63M098.5K368.0K489.9K
Selling, general and administrative10.3M1.28M648.9K271.5K529.6K
Operating income-11.9M-1.28M-747.4K-639.5K-1.02M
Depreciation and amortization5.71K0
EBITDA-11.9M-1.28M
Interest expense283.0K117.7K38.1K29.1K6.74K
Income before tax-6.00M-1.39M-777.7K-668.7K-1.03M
Net income-6.00M-1.39M-777.7K-668.7K-1.03M
Earnings per share, basic-0.55-0.18-0.17-1.45-8.08
Earnings per share, diluted-0.55-0.18-0.17

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents144.6K3.46K410.5K6.17K171.4K
Short-term investments2.00M
Current assets14.0M13.1K422.1K6.17K172.2K
Property, plant and equipment51.6K
Total assets164.2M13.1K422.1K6.17K172.2K
Accounts payable918.6K591.2K36.9K10.7K
Current liabilities10.7M1.02M123.3K319.8K10.7K
Long-term debt346.8K266.9K400.0K400.0K
Total debt7.76M596.8K266.9K660.0K400.0K
Total liabilities10.8M1.37M390.2K719.8K410.7K
Shareholders' equity153.3M-1.36M31.9K-713.6K-238.5K
Shares outstanding1.26M7.90M7.90M459.8K126.9K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-8.93M-733.5K-627.8K-448.2K-823.1K
Capital spending-57.3K0000
Free cash flow-8.98M-733.5K-627.8K-448.2K-823.1K
Cash from investing-10.1M
Cash from financing20.6M326.5K1.03M282.9K400.0K
Change in cash1.63M-407.0K404.3K-165.3K-423.1K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Material contractSEC
DEF 14A · Proxy statementNov 18, 2026Meeting noticeSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
3 · Initial statement of ownershipNov 5, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 2, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 2, 2026Insider tradeSEC
8-K · Current reportOct 13, 2026Current reportSEC
8-K · Current reportOct 1, 2026Management or board changeSEC
8-K · Current reportSep 29, 2026Current reportSEC
8-K · Current reportSep 22, 2026Current reportSEC
All 133 filings
FilingDateTypeFiled with
8-K · Current reportSep 11, 2026Material contractSEC
8-K · Current reportAug 21, 2026Material contractSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026Current reportSEC
8-K · Current reportJul 13, 2026Current reportSEC
10-Q · Quarterly reportMay 26, 2026Quarterly reportSEC
NT 10-Q · Late filing noticeMay 15, 2026Explanation requestSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 7, 2026Big-stake noticeSEC
8-K · Current reportMay 5, 2026Management or board changeSEC
10-K · Annual reportMay 4, 2026Annual reportSEC
8-K · Current reportMay 4, 2026Material contractSEC
8-K · Current reportApr 22, 2026Current reportSEC
8-K · Current reportApr 16, 2026Current reportSEC
425Apr 9, 2026Other filingsSEC
8-K/A · Current report, amendedApr 9, 2026Management or board changeSEC
NT 10-K · Late filing noticeMar 31, 2026Explanation requestSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 30, 2026Big-stake noticeSEC
8-K · Current reportMar 26, 2026Management or board changeSEC
8-K · Current reportMar 25, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 20, 2026Big-stake noticeSEC
8-K · Current reportMar 16, 2026Current reportSEC
DEFM14CFeb 26, 2026Other filingsSEC
425Feb 17, 2026Other filingsSEC
8-K/A · Current report, amendedFeb 17, 2026Acquisition or disposalSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 26, 2026Big-stake noticeSEC
PREM14CJan 16, 2026Other filingsSEC
8-K · Current reportJan 2, 2026Management or board changeSEC
8-K · Current reportDec 10, 2025Management or board changeSEC
8-K/A · Current report, amendedDec 10, 2025Material contractSEC
425Dec 2, 2025Other filingsSEC
8-K · Current reportDec 2, 2025Acquisition or disposalSEC
4/A · Change in ownership, amendedNov 21, 2025Insider tradeSEC
8-K · Current reportNov 18, 2025Management or board changeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
8-K · Current reportOct 16, 2025Current reportSEC
10-Q · Quarterly reportAug 19, 2025Quarterly reportSEC
NT 10-Q · Late filing noticeAug 14, 2025Explanation requestSEC
8-K · Current reportJul 16, 2025Current reportSEC
4/A · Change in ownership, amendedJun 11, 2025Insider tradeSEC
3/A · Initial statement of ownership, amendedJun 11, 2025Insider tradeSEC
8-K · Current reportJun 5, 2025Management or board changeSEC
S-8 · Registration statement for employee plansMay 23, 2025Offer documentSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
8-K · Current reportMay 20, 2025Material contractSEC
SCHEDULE 13D · Big-stake noticeMay 19, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 19, 2025Quarterly reportSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
NT 10-Q · Late filing noticeMay 15, 2025Explanation requestSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
3/A · Initial statement of ownership, amendedMay 14, 2025Insider tradeSEC
8-K · Current reportMay 12, 2025Material contractSEC
424B4 · ProspectusMay 8, 2025Offer documentSEC
3 · Initial statement of ownershipMay 8, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveMay 6, 2025Other filingsSEC
CORRESP · Letter to the SECMay 5, 2025Other filingsSEC
CORRESP · Letter to the SECMay 5, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 5, 2025Other filingsSEC
POS AM · Amendment to an effective registrationMay 2, 2025Offer documentSEC
CORRESP · Letter to the SECMay 1, 2025Other filingsSEC
10-K/A · Annual report, amendedMay 1, 2025Annual reportSEC
CORRESP · Letter to the SECMay 1, 2025Other filingsSEC
POS AM · Amendment to an effective registrationMay 1, 2025Offer documentSEC
UPLOAD · Letter from the SECMay 1, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 30, 2025Other filingsSEC
POS AM · Amendment to an effective registrationApr 16, 2025Offer documentSEC
10-K · Annual reportApr 15, 2025Annual reportSEC
8-K · Current reportApr 15, 2025Current reportSEC
NT 10-K · Late filing noticeMar 31, 2025Explanation requestSEC
CERT · Exchange's certificate of listingMar 4, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeMar 3, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 12, 2025Other filingsSEC
FWP · Free writing prospectusFeb 10, 2025Offer documentSEC
CORRESP · Letter to the SECFeb 10, 2025Other filingsSEC
S-1/A · Registration statement, amendedFeb 10, 2025Offer documentSEC
UPLOAD · Letter from the SECFeb 7, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 7, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 7, 2025Other filingsSEC
S-1/A · Registration statement, amendedFeb 6, 2025Offer documentSEC
S-1/A · Registration statement, amendedJan 29, 2025Offer documentSEC
S-1/A · Registration statement, amendedJan 10, 2025Offer documentSEC
S-1/A · Registration statement, amendedDec 20, 2024Offer documentSEC
CORRESP · Letter to the SECDec 19, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 16, 2024Other filingsSEC
S-1/A · Registration statement, amendedDec 9, 2024Offer documentSEC
S-1/A · Registration statement, amendedNov 8, 2024Offer documentSEC
S-1 · Registration statementSep 25, 2024Offer documentSEC
DRSLTR · Letter to the SEC with a draftAug 2, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedAug 2, 2024Offer documentSEC
DRSLTR · Letter to the SEC with a draftJun 14, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedJun 14, 2024Offer documentSEC
UPLOAD · Letter from the SECMay 23, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftMay 13, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedMay 13, 2024Offer documentSEC
UPLOAD · Letter from the SECFeb 26, 2024Other filingsSEC
DRS · Draft registration statementJan 29, 2024Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Apimeds Pharmaceuticals US, Inc.’s releases · as of Dec 10, 2025

Common shares
1,509,118
Fully diluted
1,509,118

Fully diluted

LineShares
Common shares1,509,118

Share count over time

CountShares
Nov 22, 20261,509,118

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Hemenway Trust Co LLC27,4001.5%US$137KSep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund51,6202.8%US$46,458Jun 30, 2026
Fidelity Extended Market Index Fund27,3341.5%US$38,541May 31, 2026
Vanguard Institutional Total Stock Market Index Fund12,0340.65%US$10,831Jun 30, 2026
Fidelity Series Total Market Index Fund9,7290.53%US$13,718May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Inscobee Inc.16.70%2.1MMay 7, 2026Schedule 13D
Ayrton Capital LLC9.99%1.4MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Elona Kogan
Other companies: Seer, Inc. (CHIEF LEGAL OFFICER · Dec 3, 2020 – Feb 6, 2024 · Past); Cartesian Therapeutics, Inc. (General Counsel · Mar 20, 2019 – Jan 2, 2020 · Past); Ariad Pharmaceuticals Inc (Sr. V. P. - General Counsel · Jul 15, 2016 – Feb 16, 2017 · Past)
Director · Since at least Mar 4, 2025
Bennett WeintraubDirector · Since at least Mar 25, 2026
Brian PetersSenior Vice President, ai² Division · Since at least Nov 10, 2025
Carol O’DonnellDirector · Since at least Mar 25, 2026
Christopher KimChief Scientific Officer · Since at least Nov 5, 2026
Eric SherbChief Financial Officer · Since at least Nov 5, 2026
Erik C EmersonChief Executive Officer, Director · Since at least Mar 4, 2025
Hankil YoonDirector · Since at least Mar 4, 2025
Jakap KooDirector · Since at least Mar 4, 2025
Sungjoon ChaeCo-Chief Executive Officer · Since at least May 5, 2026
All 12 people
PersonSeat
Susan KramerSenior Vice President, Development · Since at least Jul 15, 2025
Vin MenonChief Executive Officer and Director · Since at least Nov 3, 2026

Open People

Log in to ask 6ix AI your own questions about Apimeds Pharmaceuticals US, Inc.